05376nam 2201429z- 450 991059507290332120231214133423.0(CKB)5680000000080797(oapen)https://directory.doabooks.org/handle/20.500.12854/92141(EXLCZ)99568000000008079720202209d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierClinical Utility of Applying PGx and Deprescribing-Based Decision Support in PolypharmacyFuture PerspectivesBaselMDPI Books20221 electronic resource (224 p.)3-0365-5162-X 3-0365-5161-1 Polypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug–drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug–drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling; the application of PGx-based guidance and/or decision tools for drug–gene and drug–drug gene interactions; medication reviews; development and application of deprescribing tools; and drivers and barriers to overcome for successful implementation in the healthcare system.Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy MedicinebicsscPharmaceutical industriesbicsscacute kidney injuryearly biomarkerplasma neutrophil gelatinase-associated lipocalinsoluble urokinase plasminogen activator receptormedication optimizationolder patientsemergency departmentmultimorbiditypolypharmacypotentially inappropriate medication useolder adultsprevalencedeterminantschronicoutpatient2019 Beers criteriaEthiopiapharmacogenomicspersons with diabetesdrug–drug interactionsdrug–gene interactionscytochrome P450SLCO1B1drug interaction checkersadverse drug reactionspharmacogeneticspersonalized medicinephenprocoumonDOACsbleedingthromboembolismHLAdrug hypersensitivityabacavirallopurinolflucloxacillinantiepileptic drugscost-effectivenessshared medication recordmedication reconciliationdrug information servicehospital pharmacy serviceelectronic prescribingelectronic medical recordclinical pharmacistCYP2D6CYP2D7PCYP2D8Pcopy number variationCNVgenotyping5’nuclease assayHRMhigh resolution meltingdrug metabolizationextracellular vesiclesexosomesmicrovesiclespharmacogene expressionmedication reviewdeprescriptionsquality of lifeagedaged, 80 and overnursing homesdeprescribingmedication-based risk scorehealth outcomescytochromesCYP1A2adverse drug reactionantipsychoticsolanzapineclozapineloxapinechildrenyouthdigital decision-supporthealth services researchgeneral practiceprocess evaluationantidepressantsutilitypopulation-basedappropriatenessmedication adherencedigital healthMedicinePharmaceutical industriesVermehren Charlotteedt1296269Westergaard NielsedtVermehren CharlotteothWestergaard NielsothBOOK9910595072903321Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy3023932UNINA